Company

NUAgo Therapeutics

Biotechnology Research Chicago, Illinois, United States 5 employees

Employees: 5
Contacts: 1
Emails: 1
Phones: 1

nuagotherapeutics.com LinkedIn

NUAgo Therapeutics Overview

Headquarters: Chicago, Illinois, United States
Website: nuagotherapeutics.com
Industry: Biotechnology Research
Employees: 5
Founded: 2020
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

London

About NUAgo Therapeutics

NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues. No longer bound to the treatment restrictions imposed due to patient and tumor heterogeneity, NUAgo's short RNAs offer the promise shift to potentially shift cancer therapy toward a chronic-like condition with periods of complete response or tumor elimination. Reach out to us if you would like to learn more.

NUAgo Therapeutics Contact Details

People in AeroLeads: 2
With contact data: 1
Email contacts: 1; 50.0% coverage
Phone contacts: 1; 50.0% coverage

NUAgo Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Robert Schickel, Ph.d.	CEO and Co-founder, Nuago Therapeutics	Amsterdam, North Holland, Netherlands	Email Phone
Marcus Peter	Professor at Northwestern University - the Feinberg School of Medicine	Chicago, Illinois, United States	View